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Abstract
Background and Objectives Lesinurad is a selective uric
acid reabsorption inhibitor (SURI) under investigation for
the treatment of gout. This study elucidated the interaction
of lesinurad with major liver and kidney transporters
in vitro and evaluated the drug–drug interactions (DDIs) of
lesinurad and atorvastatin, metformin, and furosemide in
clinical studies.
Methods Lesinurad interaction with membrane trans-
porters was evaluated in validated transporter-expressing
cell systems and analyzed by liquid scintillation counting.
Healthy male subjects (ages 18–65 years; body mass index
18–32 kg/m2) received atorvastatin (40 mg; n = 28) with
or without lesinurad 200 or 400 mg, or received metformin
(850 mg; n = 12) or furosemide (40 mg; n = 11) with or
without lesinurad 400 mg. Plasma concentrations of each
concomitant drug were determined by validated liquid
chromatography with tandem mass spectrometry methods.
Results Lesinurad interacted in vitro with OATP1B1,
OCT1, and OAT1/3 transporters. Co-administration of
lesinurad 200 mg did not significantly alter plasma expo-
sure (maximum concentration [Cmax] and area under the
concentration–time curve [AUC]) of total atorvastatin
(atorvastatin ? hydroxyl-metabolites) or atorvastatin,
while co-administration of lesinurad 400 mg increased the
Cmax of total atorvastatin and atorvastatin by 17–26 %, but
had no effect on AUC. Co-administration of lesinurad
400 mg had no effect on the plasma exposure of met-
formin. Furosemide plasma AUC was reduced by 31 % in
the presence of lesinurad 400 mg, but furosemide renal
clearance and diuretic activity were unchanged.
Conclusions No clinically relevant DDIs were observed
between lesinurad and substrates of major liver or kidney
transporters.
Key Points
Potential interactions between lesinurad and major
liver or kidney transporters were identified in vitro.
Atorvastatin, metformin, and furosemide are drugs
that interact with OATP1B1/3, OCT1/2, and OAT1/3
transporters.
Drug–drug interaction studies showed no clinically
relevant interaction between lesinurad and these
drugs.
1 Introduction
Gout is a chronic progressive inflammatory arthritis char-
acterized by the deposition of monosodium urate crystals in
musculoskeletal structures (e.g., joints), kidneys, and other
connective tissues, which results from high concentrations
of serum uric acid (sUA) [1]. For long-term management of
gout, maintenance of sUA levels below 6.0 mg/dL (below
5.0 mg/dL for greater disease severity) with urate-lowering
therapy is recommended [2]. The recommended first line of
therapy are the xanthine oxidase inhibitors (XOIs)
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allopurinol and febuxostat that reduce uric acid production
to lower sUA [2–4]. If the target sUA level cannot be
maintained with an XOI at the appropriate dose, treatment
guidelines recommend combination therapy that includes
an XOI with a uricosuric [2–4].
Lesinurad (Zurampic; AstraZeneca Pharmaceuticals,
Wilmington, DE, USA) is a novel selective uric acid
reabsorption inhibitor (SURI) approved in the USA for the
treatment of gout in combination with an XOI. Lesinurad
inhibits URAT1, the uric acid transporter mainly respon-
sible for reabsorption of uric acid from the glomerular
ultrafiltrate into the epithelial cells of the renal proximal
convoluted tubule [5]. The combination of lesinurad and an
XOI lowers sUA by increasing fractional excretion of uric
acid [6] and reducing uric acid production.
Drug exposure is dependent on the absorption, distribu-
tion, metabolism, and excretion of the drug, and transporters
expressed in the kidney and liver have been increasingly
acknowledged to play a major role in these processes [7].
These transporters are classified into two superfamilies: the
solute carrier family (including organic anion transporter
[OAT], organic anion transporter polypeptide [OATP],
organic cation transporter [OCT], and multidrug and toxic
exclusion [MATE] transporters) and the ATP-binding cas-
sette protein family (such as permeability glycoprotein [P-
gp] and breast cancer resistance protein [BCRP]) [7, 8]. The
US Food and Drug Administration (FDA) has recommended
conducting in vitro and in vivo studies on a specific group of
transporters, including OATP1B1, OATP1B3, OAT1,
OAT3, and OCT2, during drug development to evaluate the
potential for drug–drug interactions [9].
Here, we report the in vitro interaction of lesinurad with
major liver and kidney transporters. We also report clinical
studies undertaken to evaluate the potential inhibitory
effect of single doses of lesinurad (200 and 400 mg) on the
pharmacokinetics of a single dose of atorvastatin, met-
formin, or furosemide, all of which are known substrates
for major liver or kidney transporters [7].
2 Methods
2.1 In Vitro Studies
Validated oocytes, HEK293, MDCK-II, Caco-2 or MDCK-
MDR1 cell systems were used to study the interaction of
lesinurad with membrane transporters localized to the kidney
(OAT1, OAT3, OCT2, MATE1, and MATE2K) or liver (P-
gp, BCRP, OATP1B1, OATP1B3, and OCT1) [10, 11].
Xenopus laevis oocytes were injected with OAT1 or OAT3
cRNA or control (water) while HEK293 cells were stably
transfected with MATE1, MATE2K, or vector and MDCK-II
cells with hOATP1B1, hOATP1B3, hOCT1, hOCT2, or
vector. The MDCKII cell line was stably transfected with the
human MDR1 gene to create a P-gp cell line. The interaction
of lesinurad with BCRP relied on the endogenous expression
in Caco-2 cells. All cells were cultured with growth medium
according to standard methodology. In order to determine
whether lesinurad was a substrate for a transporter, cells were
incubated with [14C]-labeled lesinurad at various concentra-
tions and the amount of lesinurad taken up by the cells
determined by subtracting the uptake in vector cells from that
in the transfected cells. The uptake of a [3H]-labeled known
substrate of the transporter served as the positive control.
Inhibition of a transporter by lesinurad was determined by
incubating cells with a fixed concentration of [3H]-labeled
known substrate and various concentrations of unlabeled
lesinurad. Inhibition by a known inhibitor of each transporter
served as the positive control. Cells were incubated for the
appropriate amount of time (see Table 1). All reactions were
terminated by the addition of ice-cold medium. The cells were
then rinsed with medium and lysed.
2.1.1 Analytical Method
Uptake of [14C]-labeled lesinurad or [3H]-labeled known
substrates was measured by liquid scintillation counting
(Perkin Elmer, Waltham, MA, USA and Hitachi Aloka,
Tokyo, Japan). Transporter-mediated uptake was calcu-
lated by subtracting uptake in the non-transfected cells
from uptake in the transfected cells. The inhibitor con-
centration giving half-maximum inhibition (IC50) was
calculated by:
% of control ¼ 100  IC50= IC50 þ I½ ð Þ
where [I] is the inhibitor concentration (lM).
The IC50 was not calculated if inhibition C50 % was not
observed at any tested lesinurad concentration.
2.2 Clinical Pharmacology Studies
2.2.1 Study Design
The two clinical studies were open-label, randomized,
phase I studies to investigate the effect of single-dose
lesinurad on the pharmacokinetics of atorvastatin, met-
formin, or furosemide in healthy male subjects.
In the first study, a two-cohort design was adopted for
evaluation of single doses of lesinurad with atorvastatin, in
which subjects were randomized 1:1 to either lesinurad
200 mg with or without atorvastatin or lesinurad 400 mg
with or without atorvastatin. Subjects received lesinurad
200 or 400 mg on day 4 and a single dose of atorvastatin
40 mg on days 1 and 4. Atorvastatin and lesinurad were
given in the morning, approximately 30 min after con-
sumption of a standard breakfast. The study was conducted
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99 4.3 Yes 0.06
5 lM lesinurad 46
25 lM lesinurad 87
OAT3 Oocytes/60 min 2 lM estrone-3-sulfate 200 lM
bumetanide
97 3.5 Yes 0.08
5 lM lesinurad 64
25 lM lesinurad 95
OCT2 MCDK-II/5 min 10 lM metformin 100 lM quinidine 78 [300 No \0.001
3 lM lesinurad 10
30 lM lesinurad 6
100 lM lesinurad 26
300 lM lesinurad 18
MATE1 HEK293/2 min 5 lM
tetraethylammonium





1 lM lesinurad 9
10 lM lesinurad 2
100 lM lesinurad 20
MATE2K HEK293/2 min 10 lM
tetraethylammonium





1 lM lesinurad -21
10 lM lesinurad -16
100 lM lesinurad -9
Liver transporters
OATP1B1 MCDK-II/5 min 2 lM
bromosulfophthalein
100 lM rifampicin 99 9.3 Yes 1.8
3 lM lesinurad 25
30 lM lesinurad 80
OATP1B3 MCDK-II/5 min 2 lM
bromosulfophthalein
100 lM rifampicin 98 43.1 Minor 0.39
3 lM lesinurad 21
30 lM lesinurad 49
OCT1 MCDK-II/5 min 10 lM metformin 100 lM quinidine 77 13.7 Yes 2.9
3 lM lesinurad 36
30 lM lesinurad 58
BCRP Caco-2/120 min 25 nM genistein 100 lM chrysin 92 [3000 Minor \0.006
3 lM lesinurad 18
30 lM lesinurad 27
100 lM lesinurad 38
P-gp MDCK-MDR1/
120 min
100 nM digoxin 50 lM
ketoconazole
100 1000 No 0.02
3 lM lesinurad -6
30 lM lesinurad -3
100 lM lesinurad -6
BCRP breast cancer resistance protein, Cmax maximum concentration, IC50 half maximum inhibitory concentration, OAT organic anion trans-
porter, OATP organic anion transporter polypeptide, OCT organic cation transporter, MATE multidrug and toxic exclusion, P-gP permeability
glycoprotein
a Cmax/IC50 ratio: for kidney transporter, Cmax (200 mg dose) is approximately 17.1 lM, using 98.4 % as protein-bound fraction for the
calculation of free lesinurad concentration; for liver transporter, Cmax (200 mg dose) total concentration (approximately 17.1 lM) was used
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at a single clinical research facility (Overland Park, KS,
USA) between 11 June 2011 and 1 August 2011.
In the second study, a two-sequence, two-period, cross-
over design was used to evaluate single-dose lesinurad
400 mg in combination with metformin 850 mg or fur-
osemide 40 mg in subjects randomized 1:1 to one of two
sequences within each separate cohort: metformin or fur-
osemide on day 1 followed by lesinurad plus metformin or
furosemide on day 5 or lesinurad plus metformin or fur-
osemide on day 1 followed by metformin or furosemide on
day 5. Lesinurad and metformin or lesinurad and furosemide
were orally administered with 240 mL of water after an
overnight fast of at least 10 h. No food was allowed for 4 h
after the study treatments were given. Subjects were
required to remain well hydrated, with a minimum fluid
intake of 2–2.5 L per day. A larger fluid intake was neces-
sary for furosemide-treated subjects, in whom consumption
was guided by thirst. The study was conducted at a single
clinical research facility (Kalamazoo, MI, USA) between 29
October 2013 and 18 December 2013.
The studies were conducted in accordance with the
Declaration of Helsinki and International Conference on
Harmonisation Good Clinical Practice (ICH GCP) guide-
lines. The protocol, protocol amendments, and written
informed consent form were approved by an institutional
review board. Subjects provided written informed consent
prior to study participation.
2.2.2 Study Population
Males between 18 and 65 years of age, with a body weight
above 50 kg and a body mass index within the range of 18
and 30 kg/m2, were eligible. Subjects were also required to
be free of significant disease necessitating physician care or
interfering with study evaluations or procedures and to
have normal measurements for laboratory parameters
(chemistry, hematology, urinalysis), physical examination,
vital signs, or electrocardiogram.
Key exclusion criteria were inadequate venous access or
unsuitable veins for repeated venipuncture; concomitant
chronic or acute illness or an acute febrile illness within
1 week of dose administration; history or current symp-
toms of renal calculi or gout; major surgery within
3 months prior to first dose; clinically relevant intolerance
or allergy to foods or drugs (including statins), or known or
suspected hypersensitivity to any ingredient in the inves-
tigational products; history of drug addiction or excessive
alcohol use; and previous participation in a lesinurad study.
2.2.3 Pharmacokinetic Sample Collection
For determination of atorvastatin pharmacokinetics, blood
samples were collected on day 1 and day 4 pre-dose (within
30 min before dosing) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6,
8, 12, 16, 24, 30, 36, 48, 60, and 72 h post-dose. For
metformin or furosemide, blood samples were collected at
the following times on days 1 and 5: pre-dose (within
30 min before dosing) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8,
10, 12, 14, and 24 h post-dose. Urine pharmacokinetics
were assessed over post-dose intervals of 0–6, 6–12, and
12–24 h on day 1 and day 5 of treatment with furosemide.
2.2.4 Pharmacokinetic Sample Analyses
All analyses were conducted using previously validated high-
performance liquid chromatography-tandem mass spectrom-
etry (HPLC–MS/MS) methods. Plasma samples were ana-
lyzed for atorvastatin and metabolites by Tandem Labs (Salt
Lake City, UT, USA) and for metformin and furosemide by
PPD (Richmond, VA, USA). Urine samples were analyzed for
furosemide by inVentive Health Clinique, Inc. (Quebec City,
Quebec, Canada). In plasma, the calibration range was
0.3–50 ng/mL for atorvastatin, 2-OH atorvastatin and 4-OH
atorvastatin; 2.00–1000 ng/mL for metformin; and
5.00–5000 ng/mL for furosemide. In urine, the calibration
range was 100–200,000 ng/mL for furosemide.
2.2.5 Statistical Analysis: Pharmacokinetic
and Pharmacodynamic Analyses
Plasma pharmacokinetic parameters were derived using
validated WinNonlin platform (Pharsight Corporation,
Mountain View, CA, USA). The maximal plasma con-
centration (Cmax) and the time to reach Cmax (Tmax) were
calculated from individual plasma concentration–time
profiles of atorvastatin (including the metabolites 2-OH-
atorvastatin and 4-OH-atorvastatin), metformin or plasma
and urine profiles of furosemide using a non-compart-
mental method and summarized by treatment. Additional
calculated pharmacokinetic parameters included the area
under the concentration–time curve (AUC) from time zero
to the time of the last quantifiable concentration (AUClast),
AUC from time zero to infinity (AUC?), and apparent
terminal half-life. Additional pharmacokinetic parameters
for metformin and furosemide included apparent total body
clearance and volume of distribution at steady state.
Geometric mean (GMR) point estimates and 90 %
confidence intervals (CIs) of treatment differences were
calculated. For the atorvastatin study, no DDI was deemed
to have occurred if the GMR was contained within the
boundaries of equivalence (80–125 %). For the metformin
and furosemide studies, the usual criterion was employed
where no DDI was deemed to have occurred if the 90 %
CIs of the GMR were contained within the 80–125 %
boundaries. For uniformity, the results with atorvastatin
were also analyzed using the latter criterion.
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An ad hoc pharmacodynamic analysis was conducted to
assess for change in the diuretic properties of furosemide,
including urine sodium, urine volume, and specific gravity in
the presence of lesinurad. These analyses were performed
using a mixed model that incorporated treatment, time and
treatment by time interaction as fixed effects. Least squares
means and P values were calculated for the comparison
between lesinurad plus furosemide and furosemide alone.
3 Results
3.1 In Vitro Analyses
Lesinurad was determined to be a substrate for the kidney
transporters OAT1 and OAT3 with Km values of 0.85 and
2 lM, respectively; lesinurad was not a substrate for OCT2
and was not evaluated for MATE1 or MATE2K (Table 1).
Of the liver transporters, lesinurad was a weak substrate for
OCT1 (Km of *20 lM) and OATP1B1. As a substrate for
OATP1B1, lesinurad was only tested at 10 lM, where a
2.25-fold increase in lesinurad uptake was observed in
transfected cells versus non-transfected cells. Lesinurad
was a minor substrate for BCRP, but was not a substrate for
OATP1B3 or P-gp.
Inhibition of the transport of known substrates of major
kidney and liver transporters by lesinurad and known
inhibitors is shown in Table 1. The greatest inhibition by
lesinurad was observed with the kidney transporters OAT1
and OAT3 and the liver transporter OATP1B1, less inhi-
bition was observed with OCT1 and OATP1B3, and little
or no inhibition with OCT2, P-gp, BCRP, MATE1, and
MATE2K. The calculated Cmax/IC50 ratio suggested that
lesinurad may have a higher potential to inhibit OATP1B1
(1.8) followed by OCT1 (1.2) and OATP1B3 (0.39) clini-
cally and is not considered to be an inhibitor of OAT1
(0.06), OAT3 (0.08), P-gp (0.02), BCRP (\0.006), OCT 2
(\0.001), MATE1, or MATE2K. To assess the in vivo
relevance of these in vitro findings, clinical pharmacology
studies evaluated the effect of lesinurad on the pharma-
cokinetics of atorvastatin (OATP1B1 substrate), metformin
(OCT1 substrate), and furosemide (OAT1/3 substrate).
3.2 Clinical Pharmacology Studies
3.2.1 Study Population
In the first study, 28 subjects were randomized to lesinurad
200 mg (n = 14) or 400 mg (n = 14) and atorvastatin. All
28 completed the study. The study population comprised
male subjects, white (46.4 %) and black (46.4 %), with a
mean (SD) age of 35 (13) years and body mass index of
26.6 (2.4) kg/m2.
In the second study, 23 subjects received lesinurad and
metformin (n = 12) or furosemide (n = 11); none dis-
continued the study. Subjects were male, white (91.3 %),
with a mean (SD) age of 33 (9) years and body mass index
of 24.9 (2.5) kg/m2. Baseline characteristics were similar
between groups in both studies.
3.2.2 Effect of Lesinurad on Atorvastatin
Pharmacokinetics
The plasma concentration–time profile of a single dose of
atorvastatin 40 mg alone and in combination with a single
dose of lesinurad 200 mg or in combination with lesinurad
400 mg are presented in Fig. 1a, b, respectively. Atorvas-
tatin exposure, as noted by the geometric mean (95 % CI)
for Cmax and AUC, was not significantly altered by co-
administration with lesinurad at either dose (Table 2). No
DDI between atorvastatin and 200 mg lesinurad was
deemed to have occurred as the GMR and the 90 % CI of
the GMR for Cmax and AUC? were contained within the
80–125 % boundaries (Table 3). Lesinurad did increase the
Cmax (16 %) and AUC? (20 %) of 2-OH-atorvastatin. The
Cmax of atorvastatin, total atorvastatin and 2-OH-atorvas-
tatin was increased 17–34 % by the addition of lesinurad
400 mg, as the upper bound of the 90 % CIs were above
the 125 % upper boundary. The AUC for atorvastatin, total
atorvastatin, and 2-OH-atorvastatin were not significantly
altered by the co-administration of lesinurad (Table 3). The
minor metabolite, 4-OH-atorvastatin, was evident at only
trace plasma concentration levels, so it was not possible to
characterize its pharmacokinetics.
3.2.3 Effect of Lesinurad on Metformin or Furosemide
Pharmacokinetics
The plasma concentration–time profile of a single dose of
metformin 850 mg alone and in combination with a single
dose of lesinurad 400 mg, and a single dose of furosemide
40 mg alone and in combination with lesinurad 400 mg are
presented in Fig. 1c, d, respectively. With metformin, there
were no marked differences in the GMR (95 % CI) for
metformin pharmacokinetic parameters in the presence
versus absence of lesinurad (Table 2). The 90 % CIs
around the GMRs for metformin Cmax and AUC were
entirely contained within the 80–125 % boundaries
(Table 3).
With furosemide, the co-administration of lesinurad
increased median Tmax from 1 h to 2 h post-dose, and Cmax
and AUC values were lower than with furosemide alone
(Table 2). Co-administration with lesinurad reduced the
furosemide Cmax by 51 % and AUC by 31 %, with the
90 % CIs around the GMR for both Cmax and AUC not
contained within the 80–125 % boundaries (Table 3).
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Consistent with the reduction in plasma exposure, the
amount of furosemide excreted in urine was reduced by
approximately 25 % in the presence of lesinurad. The
GMR (95 % CI) for renal clearance (CLR) of furosemide
was 99.3 (89.2–111) mL/min and 107 (97.5–119) mL/min
in the absence and presence of lesinurad, respectively. CLR
was unchanged by lesinurad, as the GMR and the 90 % CI
around the GMR for CLR fell within the 80–125 %
boundaries (Table 3).
There was no clinically significant impact of lesinurad
on the activity of furosemide based on an assessment of
urine flow rate, volume, sodium concentration, and specific
gravity at each urine collection interval (Table 4).
4 Discussion
There is increasing awareness of the importance of
understanding DDIs between gout treatments and con-
comitantly administered drugs [12, 13]. A series of
in vitro studies were undertaken to establish the potential
for transporter-mediated DDIs between lesinurad and
commonly used drugs in patients with gout following the
FDA Drug Interaction Guidance [9]. Using validated
in vitro cell systems expressing specific transport proteins,
it was shown that lesinurad was associated with a
potential to inhibit the liver transporter OATP1B1 and, to
a lesser extent, OCT1 and OATP1B3. The in vitro
investigations also indicated that inhibition of the major
kidney transporters, OAT1 and OAT3, by lesinurad was
minimal, and no inhibition of OCT2 was expected.
Results from the in vitro analyses also suggested that
lesinurad is unlikely to exert an effect on MATE1 and
MATE2K, which are transporters involved in the regu-
lation of serum creatinine and the renal elimination of
drugs [14, 15].
DDIs between lesinurad and commonly used drugs
known to be substrates of the kidney or liver transporters
identified in the in vitro analyses were investigated in
clinical pharmacology studies. Atorvastatin is a substrate of
the liver transporter OATP1B1 [7, 16, 17], which was
identified as potentially being inhibited by lesinurad.
However, our study showed that lesinurad 200 mg did not
significantly alter the pharmacokinetics of atorvastatin,
while there was a slight increase in atorvastatin exposure
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Fig. 1 Median plasma concentration profiles for total atorvastatin
(including metabolites) following a single oral dose of atorvastatin
40 mg in the absence or presence of a single dose of lesinurad 200 mg
(a) or 400 mg (b), and plasma concentration profile of metformin
following a single dose of metformin 850 mg (c) or plasma
concentration profile of furosemide following a single dose of
furosemide 40 mg (d) in the absence or presence of a single dose of
lesinurad 400 mg
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atorvastatin pharmacokinetics following lesinurad single
dosing suggest there was no clinically relevant inhibition of
OATP1B1 activity by lesinurad in vivo. It should be noted
that these results should also be applicable to chronic,
once-daily treatment with lesinurad, since lesinurad does
not accumulate during multiple once-daily dosing. The
results with lesinurad are in contrast to those with rifampin
(rifampicin), a strong inhibitor of OATP1B1 in which an
intravenous infusion of 600 mg of rifampin 30 min before
a single atorvastatin 40 mg oral dose increased the expo-
sure of atorvastatin by 3.9- to 6.8-fold [16]. The difference
is not readily explained by differences in in vitro IC50
values (lesinurad, *9 lM; rifampin, *3 lM) or maxi-
mum plasma drug concentration (lesinurad, *44 nM;
rifampin, *17 nM). However, rifampin has lower protein
binding (80 %) than lesinurad (98 %) so the free concen-
tration available to inhibit OATP is higher for rifampin
than for lesinurad. In addition, different substrates were
used to determine the IC50 values, estradiol-glucuronide for
lesinurad and atorvastatin for rifampin. OATPs have been
shown to have multiple binding sites [18]. Rifampin and
atorvastatin compete for the same binding site whereas
lesinurad and atorvastatin do not, and this difference may
be responsible for the difference between lesinurad and
rifampin on atorvastatin pharmacokinetics in vivo. Since
atorvastatin was not used to test the inhibitory potential of
lesinurad in vitro, the in vitro did not predict well the lack
of clinical DDI between lesinurad and atorvastatin.
The plasma exposure of metformin 850 mg was
unchanged in the presence of lesinurad. The transporters
that govern metformin pharmacokinetics and pharmaco-
dynamics are different [19]. The elimination of metformin
is solely via renal secretion (OCT2 and MATEs). Since
lesinurad does not inhibit the kidney transporters involved
in metformin renal clearance, the lack of metformin phar-
macokinetics modulation by lesinurad was not unexpected.
These recent data [19], which were not available at the time
this study was designed, suggest that OCT1 interactions
with metformin can only be detected by monitoring its
pharmacodynamic effect. The distribution of metformin
into the liver is mainly a pharmacodynamic effect as liver
is the target organ for efficacy and metformin does not
undergo extensive metabolism or biliary excretion. The
liver transporter OCT1 was identified as potentially being
inhibited by lesinurad, which could affect the pharmaco-
dynamics of metformin. However, determination of
Table 3 Geometric mean ratios (GMRs) (90 % confidence interval) for atorvastatin, metformin, and furosemide in the presence versus absence
of lesinurad
Treatment Analyte Parameter GMR (90 % CI)
Atorvastatin 40 mg ? lesinurad 200 mg vs. atorvastatin 40 mg (n = 14) Atorvastatin Cmax 0.919 (0.803–1.05)
AUC? 0.962 (0.898–1.03)
Total atorvastatin Cmax 1.01 (0.879–1.16)
AUC? 1.07 (0.980–1.17)
2-OH-atorvastatin Cmax 1.16 (0.991–1.36)
AUC? 1.20 (1.08–1.34)
Atorvastatin 40 mg ? lesinurad 400 mg vs. atorvastatin 40 mg (n = 14) Atorvastatin Cmax 1.17 (0.940–1.46)
AUC? 1.01 (0.913–1.11)
Total atorvastatin Cmax 1.26 (1.05–1.50)
AUC? 1.08 (1.00–1.18)
2-OH-atorvastatin Cmax 1.34 (1.15–1.55)
AUC? 1.17 (1.07–1.27)
Metformin 850 mg ? lesinurad 400 mg vs. metformin 850 mg (n = 12) Metformin Cmax 1.06 (1.00–1.13)
AUClast 1.02 (0.908–1.15)
AUC? 1.03 (0.911–1.15)





Cmax maximum observed concentration, AUClast area under the concentration–time curve from time zero to the last quantifiable sampling time
point (Tlast), AUC? area under the plasma concentration–time curve from time zero to infinity, extrapolated from Tlast to infinity based on the
terminal elimination rate constant kz, Ae0–24 amount excreted in urine from time zero to 24 h post-dose, CI confidence interval, CLR(0–24) renal
clearance from time zero to 24 h post-dose
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metformin pharmacodynamics was not considered at the
time of study design.
Lesinurad reduced furosemide exposure as reflected by
the decrease in furosemide Cmax and AUC and the
decreased urinary excretion of furosemide. However, the
CLR of furosemide was unaffected by co-administration of
lesinurad, denoted by the fact that 90 % CIs of the GMR
for CLR remained within the 80–125 % boundaries. Thus,
the reduced exposure is likely due to interference with
furosemide absorption by lesinurad. Despite the reduced
exposure, the diuretic activity of furosemide was unaf-
fected. A similar lack of effect on the diuretic activity of
furosemide, despite reduced furosemide exposure, has been
reported with co-administration of the angiotensin II
antagonist valsartan [20], a known inhibitor of OAT1/3
[10]. Overall, the results with furosemide do not support an
effect of lesinurad on OAT1 or OAT3 activity.
5 Conclusion
In vitro studies suggested a potential interaction of lesin-
urad with the transporters OATP1B1, OCT1, and OAT1/3.
However, in healthy subjects, no clinically relevant DDIs
were found between lesinurad and atorvastatin, metformin,
or furosemide, drugs that are known substrates for the
respective transporters. Therefore, no DDIs are anticipated
in patients with gout who are taking lesinurad and these
concomitant drugs.
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